Michael R. Megna Sells 17,000 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock

Key Points

• Michael R. Megna, CAO of Kiniksa Pharmaceuticals, sold 17,000 shares at an average price of $32.35, totaling approximately $549,950, reducing his holdings by nearly 34% to 33,041 shares.
• Kiniksa Pharmaceuticals reported earnings of $0.23 per share, exceeding analysts' expectations, and generated $156.80 million in revenue for the recent quarter.
• Analysts have a favorable outlook on Kiniksa, with several raising target prices and ratings, resulting in an average price target of $41.17 and a consensus rating of "Buy."

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CAO Michael R. Megna sold 17,000 shares of the business's stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $32.35, for a total transaction of $549,950.00. Following the completion of the sale, the chief accounting officer directly owned 33,041 shares of the company's stock, valued at approximately $1,068,876.35. This trade represents a 33.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Kiniksa Pharmaceuticals International Price Performance

Kiniksa Pharmaceuticals International stock traded down $0.96 during mid-day trading on Friday, reaching $32.15. 675,329 shares of the company traded hands, compared to its average volume of 703,396. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $33.98. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of 803.95 and a beta of 0.14. The firm's fifty day moving average is $28.95 and its two-hundred day moving average is $24.59.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. As a group, equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Wells Fargo & Company upped their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 9th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $41.17.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Creative Planning acquired a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter worth $358,000. SG Americas Securities LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 1,746.7% in the second quarter. SG Americas Securities LLC now owns 134,404 shares of the company's stock worth $3,719,000 after acquiring an additional 127,126 shares during the period. Acadian Asset Management LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 22.6% in the second quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company's stock worth $35,067,000 after acquiring an additional 233,668 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Kiniksa Pharmaceuticals International by 56.0% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 623,689 shares of the company's stock worth $17,257,000 after acquiring an additional 223,946 shares during the period. Finally, Fox Run Management L.L.C. increased its stake in shares of Kiniksa Pharmaceuticals International by 214.9% in the second quarter. Fox Run Management L.L.C. now owns 35,743 shares of the company's stock worth $989,000 after acquiring an additional 24,391 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.